Based on the IPS of HCC patients, the response to immunotherapy targeted specifically at CTLA-4 and PD-1 in high-risk and low-risk HCC patients was examined using a subclass mapping approach. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.